OREANDA-NEWS. April 17, 2012. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched RANMARK® (Subcutaneous Injection 120 mg) (INN: Denosumab (genetic recombination); Approval to market: January 18, 2012; NHI drug price listing: April 17, 2012) in Japan as a treatment for bone complications stemming from multiple myeloma and bone metastases from solid tumors.

 
RANMARK® is the world’s first human monoclonal antibody to target RANK ligand. It has been shown that RANMARK® suppresses the occurrence of SRE (skeletal-related events) in patients with bone complications stemming from multiple myeloma and bone metastases from solid tumors.
 

Daiichi Sankyo and AstraZeneca KK (an affiliate of AstraZeneca PLC) entered into a co-promotion agreement in Japan for RANMARK on May 24, 2011.

 
With denosumab, Daiichi Sankyo aims to benefit patients, their families, and medical professionals by augmenting the few available therapeutic alternatives for treating bone disorders stemming from multiple myeloma and bone metastases from solid tumors with a new and effective treatment option.